Potential targets for glucagon-like peptide 2 (GLP-2) in the rat: distribution and binding of i.v. injected (125)I-GLP-2
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Potential targets for glucagon-like peptide 2 (GLP-2) in the rat : distribution and binding of i.v. injected (125)I-GLP-2. / Thulesen, J; Hartmann, B; Orskov, C; Jeppesen, P B; Holst, J J; Poulsen, Steen Seier.
In: Peptides, Vol. 21, No. 10, 10.2000, p. 1511-7.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Potential targets for glucagon-like peptide 2 (GLP-2) in the rat
T2 - distribution and binding of i.v. injected (125)I-GLP-2
AU - Thulesen, J
AU - Hartmann, B
AU - Orskov, C
AU - Jeppesen, P B
AU - Holst, J J
AU - Poulsen, Steen Seier
PY - 2000/10
Y1 - 2000/10
N2 - Glucagon-like peptide 2 (GLP-2) is a 33-amino acid (1-33) intestinotrophic peptide. In this study, the distribution and binding of i.v. injected radiolabeled GLP-2 (1-33) were investigated in rats using autoradiography in order to target possible binding sites. The major part of (125)I-GLP-2 (1-33) was distributed to kidneys, liver, and the gastrointestinal tract. In the small intestine, a high density of grains was localized in the epithelium with a predominance in the luminal part of the villus. The saturability of (125)I-GLP-2 (1-33) was investigated by administration of excess amounts of non-radioactive GLP-2 (1-33) or the primary metabolite of GLP-2 degradation, GLP-2 (3-33). In the small intestine, (125)I-GLP-2 was displaced both by non-radioactive GLP-2 (1-33) and (3-33), suggesting that the uptake of GLP-2 (1-33) in the small intestine is receptor-specific and that the metabolite GLP-2 (3-33) may interact with the GLP-2 receptor.
AB - Glucagon-like peptide 2 (GLP-2) is a 33-amino acid (1-33) intestinotrophic peptide. In this study, the distribution and binding of i.v. injected radiolabeled GLP-2 (1-33) were investigated in rats using autoradiography in order to target possible binding sites. The major part of (125)I-GLP-2 (1-33) was distributed to kidneys, liver, and the gastrointestinal tract. In the small intestine, a high density of grains was localized in the epithelium with a predominance in the luminal part of the villus. The saturability of (125)I-GLP-2 (1-33) was investigated by administration of excess amounts of non-radioactive GLP-2 (1-33) or the primary metabolite of GLP-2 degradation, GLP-2 (3-33). In the small intestine, (125)I-GLP-2 was displaced both by non-radioactive GLP-2 (1-33) and (3-33), suggesting that the uptake of GLP-2 (1-33) in the small intestine is receptor-specific and that the metabolite GLP-2 (3-33) may interact with the GLP-2 receptor.
KW - Animals
KW - Autoradiography
KW - Binding, Competitive
KW - Epithelium
KW - Female
KW - Glucagon-Like Peptide 2
KW - Glucagon-Like Peptides
KW - Injections, Intravenous
KW - Intestine, Small
KW - Iodine Radioisotopes
KW - Kidney
KW - Liver
KW - Peptides
KW - Protein Binding
KW - Radioimmunoassay
KW - Rats
KW - Rats, Wistar
KW - Receptors, Glucagon
KW - Substrate Specificity
M3 - Journal article
C2 - 11068098
VL - 21
SP - 1511
EP - 1517
JO - Peptides
JF - Peptides
SN - 0196-9781
IS - 10
ER -
ID: 47486360